Almac to Demo Joint Service Offerings
Recently, Almac has enhanced its offerings by forming an exclusive integrated trial management alliance with Exco InTouch, a firm specializing in patient recruitment, retention, compliance, and ePRO services.The joint Almac-Exco InTouch service offering aims to enhance patient retention and compliance through the use of multiple technologies, such as SMS text messages and emails. The technology reminds patients to complete key elements of their required study obligations, such as taking medication, attending appointments, fasting prior to laboratory testing, filling out diaries, and others, while also collecting reasons for non-compliance. Working with sponsors on clinical trials, Almac will develop study-specific patient retention and compliance programs that will begin immediately upon randomization into the trial and remain in effect until the trial is completed.
Almac announced that the new joint services will be demonstrated at the DIA’s 23nd Annual EuroMeeting located in Berlin, Germany, March 27-28 and at the Partnerships in Clinical Trials Conference in Phoenix, Arizona, March 30 – April 1. In addition to featuring its the new integration with Exco InTouch, Almac will be demonstrating its IXRS® (Interactive Voice and Web Response) services and Almac’s Interactive Reporting solution, two services that were launched in 2010.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
